This site is for u.s. healthcare professionals only

ThIs site is for U.S. healthcare professionals only
Menu

STUDIED IN A LONG-TERM, PHASE III PIVOTAL TRIAL

A multicenter, randomized, open-label, Phase III trial evaluated the safety and efficacy of AURYXIA in hyperphosphatemia patients with chronic kidney disease (CKD) on hemodialysis and peritoneal dialysis over 56 weeks.1,2

Note: Duration of study periods is not represented to scale.

 

Randomization3

  • Out of the 292 patients randomized to AURYXIA during the 52-week Active Control Period, 193 completed the study
    • Of these patients, 192 were randomized 1:1 to either AURYXIA or placebo during the 4-week Placebo-Controlled Period
  • For Active Control, 149 entered the Active Control Period, with 111 completing the entire 52-week study period

 

Trial Design

The Phase III trial measured safety and efficacy endpoints over 56 weeks

PRIMARY ENDPOINT1,2:
Placebo-Controlled Period (Week 52–Week 56)

  • Change in serum phosphorus from baseline (Week 52) to Week 56 between AURYXIA and placebo

 

KEY SECONDARY ENDPOINT2:
Active Control Period (Week 0–Week 52)

  • Change in serum phosphorus from baseline (Week 0) to Week 52 between AURYXIA and
    sevelamer carbonate and/or calcium acetate

 

MAIN CRITERIA FOR INCLUSION2
  • Age ≥18 years
  • On thrice-weekly hemodialysis, or peritoneal dialysis, for at least the previous 3 months
  • Taking 3 to 18 pills/day of calcium acetate, calcium carbonate, lanthanum carbonate, and/or sevelamer (carbonate or hydrochloride or equivalent sevelamer powder), any combination of these agents, or any other agent serving as a phosphate binder
  • In addition, subjects had to have serum phosphorus ≥2.5 mg/dL and ≤8.0 mg/dL, serum ferritin <1000 ng/mL, and TSAT <50% at screening

 

EXCLUSION CRITERIA2
  • Intolerance to calcium acetate and sevelamer carbonate

 

ALLOWED THERAPIES2
  • IV iron therapy was permitted for subjects with serum ferritin ≤1000 ng/mL and TSAT ≤30%. The dose and specific intravenous (IV) iron preparation administered was at the discretion of the Investigator. The use of vitamin D and its analogues, cinacalcet, dialysate calcium concentration, and choice and dose of erythropoiesis-stimulating agent was at the discretion of the Investigator